Sažetak
Objective: To investigate the potential therapeutic benefits of autoimmune antibody detection in individuals suffering from chronic hepatitis B. Methods: For the observation group, 102 patients with chronic hepatitis B who were admitted between March 2022 and March 2025 were chosen. Additionally, the control group consisted of 102 healthy people who were examined throughout the same time period. The two groups' autoimmune antibodies were identified, and patients in the observation group with positive and negative autoimmune antibodies were compared in terms of their liver function, liver fibrosis markers, and cytokine levels. Results: The total positive rate of autoimmune antibodies in the observation group was 26.47%, whereas it was 3.92% in the control group (P<0.05). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were noticeably greater in the observation group's patients with positive autoimmune antibodies than in those with negative antibodies. However, the albumin (ALB) and total protein (TP) levels were much lower than those of patients with negative antibodies. A statistically significant difference was observed (P<0.05). Type III procollagen (PCIII), hyaluronidase (HA), and the levels of laminin (LN) were statistically significant (P<0.05) higher in individuals with positive autoimmune antibodies than in those with negative antibodies. Patients with positive autoimmune antibodies had considerably higher levels of interleukin-4 (IL-4), interleukin-10 (IL-10), and interleukin-6 (IL-6) than patients with negative antibodies. Patients with negative antibodies had significantly higher levels of interferon-γ (IFN-γ) (P < 0.05). Conclusion: Autoimmune antibodies are present in patients with chronic hepatitis B, which influence liver fibrosis indicators and related cytokines. The identification of autoimmune antibodies in chronic hepatitis B patients can serve as a guide for evaluating the illness and determining prognosis.
Ključne reči
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.